PMID- 8152163
OWN - NLM
STAT- MEDLINE
DCOM- 19940510
LR  - 20131121
IS  - 0047-1860 (Print)
IS  - 0047-1860 (Linking)
VI  - 42
IP  - 3
DP  - 1994 Mar
TI  - [Multi-center evaluation of Showa ceftizoxime disk susceptibility test to 
      discriminate between the strains of methicillin-resistant Staphylococcus aureus 
      (MRSA) and those susceptible (MSSA)].
PG  - 271-7
AB  - An increasing prevalence of methicillin-resistant Staphylococcus (S.) aureus 
      (MRSA) has a serious therapeutic problem, and accurate methods to detect such 
      strains are needed. We studied the antimicrobial susceptibility of S. aureus to 
      ceftizoxime, in comparison with those to four other cephems (cefazolin, 
      cefoxitin, latamoxef and cefmenoxime), by broth microdilutions and disk 
      susceptibility tests, and also evaluated whether the reagents, in replace of 
      penicillinase-resistant penicillins (PRPs), could discriminate between the 
      strains of MRSA and those susceptible to PRPs (MSSA). A total of 651 clinical 
      isolates of S. aureus were collected from six geographically different hospitals. 
      All the strains collected were first classified into either MRSA (n = 329) or 
      MSSA (n = 322) according to the interpretations of MRSA screening agar, minimum 
      inhibitory concentrations (MICs) to oxacillin and methicillin (NCCLS M7-A2), and 
      the presence or absence of mecA gene by polymerase chain reaction. In broth 
      microdilution tests, the MICs of MRSA to ceftizoxime ranged > or = 64 
      micrograms/ml, whereas all the MSSA were at the concentration of < or = 16 
      micrograms/ml. The results of Showa disk diffusion tests highly correlated with 
      those of MIC determinations. The distribution of inhibitory zone diameters to 
      ceftizoxime were clearly divided into two groups; 99.2% (sensitivity) of MRSA had 
      inhibitory zones of < or = 20 mm and 98.9% (specificity) of MSSA produced > or = 
      21 mm. It was concluded that the Showa ceftizoxime disk susceptibility test was 
      useful and enough reliable to screen MRSA isolates in clinical laboratories.
FAU - Moriyasu, I
AU  - Moriyasu I
AD  - Central Clinical Laboratories, Okayama Saiseikai-Sogo Hospital.
FAU - Igari, J
AU  - Igari J
FAU - Yamane, N
AU  - Yamane N
FAU - Oguri, T
AU  - Oguri T
FAU - Takahashi, A
AU  - Takahashi A
FAU - Tosaka, M
AU  - Tosaka M
FAU - Takemori, K
AU  - Takemori K
FAU - Toyoshima, S
AU  - Toyoshima S
FAU - Minamide, W
AU  - Minamide W
LA  - jpn
PT  - English Abstract
PT  - Journal Article
PT  - Multicenter Study
PL  - Japan
TA  - Rinsho Byori
JT  - Rinsho byori. The Japanese journal of clinical pathology
JID - 2984781R
RN  - C43C467DPE (Ceftizoxime)
SB  - IM
MH  - Ceftizoxime/*pharmacology
MH  - *Methicillin Resistance
MH  - Microbial Sensitivity Tests/methods
MH  - Sensitivity and Specificity
MH  - Staphylococcus aureus/*drug effects
EDAT- 1994/03/01 00:00
MHDA- 1994/03/01 00:01
CRDT- 1994/03/01 00:00
PHST- 1994/03/01 00:00 [pubmed]
PHST- 1994/03/01 00:01 [medline]
PHST- 1994/03/01 00:00 [entrez]
PST - ppublish
SO  - Rinsho Byori. 1994 Mar;42(3):271-7.